Abstract
Background
Adverse drug reactions (ADRs) represent a major cause of iatrogenic morbidity and mortality in patient care. While a substantial body of work has been undertaken to characterise ADRs in the hospital setting, the overall burden of ADRs in the primary care remains unclear.
Objectives
To investigate the prevalence of ADRs in the primary care setting and factors affecting the heterogeneity of the estimates.
Methods
Studies were identified through searching of Medline, Embase, CINAHL and IPA databases. We included observational studies that reported information on the prevalence of ADRs in patients receiving primary care. Disease and treatment specific studies were excluded. Quality of the included studies were assessed using Smyth ADRs adapted scale. A random-effects model was used to calculate the pooled estimate. Potential source of heterogeneity, including age groups, ADRs definitions, ADRs detection methods, study setting, quality of the studies, and sample size, were investigated using sub-group analysis and meta-regression.
Results
Thirty-three studies with a total study population of 1,568,164 individuals were included. The pooled prevalence of ADRs in the primary care setting was 8.32% (95% CI, 7.82, 8.83). The percentage of preventable ADRs ranged from 12.35–37.96%, with the pooled estimate of 22.96% (95% CI, 7.82, 38.09). Cardiovascular system drugs were the most commonly implicated medication class. Methods of ADRs detection, age group, setting, and sample size contributed significantly to the heterogeneity of the estimates.
Conclusion
ADRs constitute a significant health problem in the primary care setting. Further research should focus on examining whether ADRs affect subsequent clinical outcomes, particularly in high-risk therapeutic areas. This information may better inform strategies to reduce the burden of ADRs in the primary care setting.
Funder
LPDP (Indonesia Endowment Fund for Education), Ministry of Finance, Republic of Indonesia
Publisher
Public Library of Science (PLoS)
Reference119 articles.
1. World Health Organization. International Drug Monitoring: Technical Report Series No. 425. [Page 6]. Geneva: World Health Organization; 1969.
2. European Union Directive 2010/84/EU on the Community Code relating to Medicinal Products for Human Use, amending, as regards Pharmacovigilance, Directive 2001/ 83/EC. https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf [Accessed May 2020]
3. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies;J Lazarou;JAMA,1998
4. Trends in emergency hospital admissions in England due to adverse drug reactions: 2008–2015;C Jennifer;J Pharm Health Serv Res,2017
5. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005;H Patel;BMC Clin Pharmacol,2007
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献